Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 13/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 13/20 | 0.34 |
| ▸ | RRM1 | P23921 | 11/20 | 0.34 |
| ▸ | RRM2B | Q7LG56 | 11/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20872550 | 1.00 | CHRM2 (0.34) | CHRM2CHRM1RRM1RRM2BMEN1 | |
| SCHEMBL3093413 | 0.83 | MEN1 (0.33) | MEN1KMT2AACHECES2CES1 | |
| SCHEMBL13069751 | 0.83 | DAO (0.33) | MEN1KMT2AACHE | |
| SCHEMBL9945902 | 0.82 | CHRM2 (0.34) | CHRM2CHRM1RRM1RRM2BACHE | |
| SCHEMBL25015121 | 0.79 | MEN1 (0.32) | CHRM2CHRM1RRM1RRM2BMEN1 | |
| SCHEMBL29478802 | 0.79 | MEN1 (0.32) | MEN1KMT2A | |
| SCHEMBL24373240 | 0.79 | MEN1 (0.32) | MEN1KMT2A | |
| SCHEMBL3097748 | 0.79 | CHRM2 (0.32) | CHRM2CHRM1RRM1RRM2BMEN1 | |
| SCHEMBL29628526 | 0.78 | CHRM2 (0.33) | CHRM2CHRM1RRM1RRM2BACHE | |
| SCHEMBL29628524 | 0.78 | CHRM2 (0.33) | CHRM2CHRM1RRM1RRM2BACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260085067-A1 | CYCLIC SULFONAMIDE RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND USES THEREOF | BOUNDLESS BIO INC (US) | 2026-03-26 | — | — | US | disclosed |
| EP-4587437-A1 | CYCLIC SULFONAMIDE RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND USES THEREOF | Boundless Bio, Inc. (US) | 2025-07-23 | — | — | EP | disclosed |
| US-20240425490-A1 | SULFAMIDE RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND USES THEREOF | BOUNDLESS BIO, INC. | 2024-12-26 | — | — | US | disclosed |
| CN-118488945-A | Sulfonamide ribonucleotide reductase (RNR) inhibitors and uses thereof | 无界生物公司 | 2024-08-13 | — | — | CN | disclosed |
| CN-118434417-A | Cyclic sulfonamide ribonucleotide reductase (RNR) inhibitors and uses thereof | 无界生物公司 | 2024-08-02 | — | — | CN | disclosed |
| EP-4401728-A1 | CYCLIC SULFONAMIDE RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND USES THEREOF | Boundless Bio, Inc. (US) | 2024-07-24 | — | — | EP | disclosed |
| CN-111386260-B | Sulfonamide compounds and uses thereof | 大鹏药品工业株式会社 | 2024-04-30 | — | — | CN | disclosed |
| WO-2024059563-A1 | CYCLIC SULFONAMIDE RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND USES THEREOF | BOUNDLESS BIO, INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| WO-2023043923-A1 | CYCLIC SULFONAMIDE RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND USES THEREOF | BOUNDLESS BIO, INC. (US) | 2023-03-23 | — | — | WO | disclosed |
| CN-109563057-B | Sulfonamide compound or salt thereof | 大鹏药品工业株式会社 | 2022-06-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260085067-A1 | CYCLIC SULFONAMIDE RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND USES THEREOF | RRM1, RRM2B, RRM2 | CHRM2 3695/4885CHRM1 3732/4885RRM1 1/4885 |
| US-20240425490-A1 | SULFAMIDE RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND USES THEREOF | RRM2B, RRM2, RRM1 | CHRM2 4880/4885CHRM1 4885/4885RRM1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.